(thirdQuint)Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction.

 Smokeless tobacco (ST) users will be randomly assigned to either the 4-mg active nicotine lozenge or matching placebo.

 Both groups will receive a behavioral intervention.

 The two sites for this clinical trial will be the Mayo Clinic in Rochester, Minnesota (central coordinating site) and the Oregon Research Institute (ORI) in Eugene, OR.

 A total of 270 ST users will be recruited into this clinical trail.

 All subjects will be randomized to 4 mg Nicotine Lozenges (taken ad lib) or matching placebo.

 They will be on study medication for 12 weeks and followed up for 6 months from study enrollment.

 Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction@highlight

This study will be a randomized, blinded, placebo-controlled two-group clinical trial.

 The independent variable is treatment assignment (active 4-mg nicotine lozenge vs.

 matching placebo lozenge), and the dependent variables are all tobacco and ST abstinence at 3 and 6 months.

 ST users will be randomly assigned to either the 4-mg active nicotine lozenge or matching placebo.

